Clinical trial
Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of…
NCT00101894 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00101894 |
|---|---|
| Title | Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer |
| Official title | An Open-Label, Dose-Finding Study to Evaluate the Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Rectal Cancer, Colon Cancer |
| Intervention type | Biological, Drug |
| Interventions | FOLFOX-4, AMG 706, Panitumumab (Part 1a only), FOLFIRI |
| Enrollment | 119 |
| Start date | Dec 1, 2004 |
| Primary completion | Apr 1, 2010 |
| Completion | Dec 1, 2011 |
| First posted | Jan 19, 2005 |
| Last update posted | Sep 17, 2012 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: